389 related articles for article (PubMed ID: 16575472)
21. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.
Zelezníková T; Babusíková O
Neoplasma; 2005; 52(6):517-22. PubMed ID: 16284699
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.
Hoffmann MH; Klausen TW; Boegsted M; Larsen SF; Schmitz A; Leinoe EB; Schmiegelow K; Hasle H; Bergmann OJ; Sorensen S; Nyegaard M; Dybkaer K; Johnsen HE
Cytometry B Clin Cytom; 2012 May; 82(3):123-31. PubMed ID: 22328535
[TBL] [Abstract][Full Text] [Related]
23. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
Al-Mawali A; Gillis D; Hissaria P; Lewis I
Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
[TBL] [Abstract][Full Text] [Related]
24. Shifts in expression of immunological cell markers in relapsed acute leukemia.
Tomová A; Babusíková O
Neoplasma; 2001; 48(3):164-8. PubMed ID: 11583283
[TBL] [Abstract][Full Text] [Related]
25. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
26. Immunophenotyping is an independent factor for risk stratification in AML.
Repp R; Schaekel U; Helm G; Thiede C; Soucek S; Pascheberg U; Wandt H; Aulitzky W; Bodenstein H; Sonnen R; Link H; Ehninger G; Gramatzki M;
Cytometry B Clin Cytom; 2003 May; 53(1):11-9. PubMed ID: 12717686
[TBL] [Abstract][Full Text] [Related]
27. Single step immunophenotyping of acute leukemias not classifiable by standard morphology and cytochemistry: a practical approach.
Raimondi R; Pellizzari G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):66-72. PubMed ID: 8039763
[TBL] [Abstract][Full Text] [Related]
28. Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia.
Babusíková O; Glasová M; Koníková E; Kusenda J
Neoplasma; 1996; 43(6):367-72. PubMed ID: 8996560
[TBL] [Abstract][Full Text] [Related]
29. [Immunophenotyping of acute leukemias: diagnostic and pronostic utility in Abidjan, Côte d'Ivoire].
Inwoley KA; Sawadogo D; Mizero L; Salou M; Karim N; Sangaré A
Bull Soc Pathol Exot; 2004; 97(5):319-22. PubMed ID: 15787262
[TBL] [Abstract][Full Text] [Related]
30. The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Testoni N; Tosi P; Michieli M; Damiani D; Motta MR; Tura S
Stem Cells; 1995 Jul; 13(4):428-34. PubMed ID: 7549902
[TBL] [Abstract][Full Text] [Related]
31. Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance.
Bahia DM; Yamamoto M; Chauffaille Mde L; Kimura EY; Bordin JO; Filgueiras MA; Kerbauy J
Haematologica; 2001 Aug; 86(8):801-6. PubMed ID: 11522535
[TBL] [Abstract][Full Text] [Related]
32. Chronic myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype.
Mesárosová A; Hrivnáková A; Klobusická M; Babusíková O
Neoplasma; 1995; 42(1):9-14. PubMed ID: 7617076
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes.
Lorand-Metze I; Califani SM; Ribeiro E; Lima CS; Metze K
Leuk Res; 2008 Feb; 32(2):211-3. PubMed ID: 17675154
[TBL] [Abstract][Full Text] [Related]
34. Acute myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype.
Mesárosová A; Hrivnáková A; Babusíková O
Neoplasma; 1993; 40(6):341-5. PubMed ID: 8289964
[TBL] [Abstract][Full Text] [Related]
35. [Flow cytometric analysis of myeloperoxidase negative acute unclassifiable leukemias by monoclonal antibodies. Acute myelogenous and acute megakaryocytic leukemia].
Imamura N; Kuramoto A; Kawaguchi Y; Tanaka R
Rinsho Ketsueki; 1989 Jan; 30(1):11-21. PubMed ID: 2541276
[TBL] [Abstract][Full Text] [Related]
36. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray.
Belov L; de la Vega O; dos Remedios CG; Mulligan SP; Christopherson RI
Cancer Res; 2001 Jun; 61(11):4483-9. PubMed ID: 11389079
[TBL] [Abstract][Full Text] [Related]
38. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
39. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
40. Haematologic and immunophenotypic profile of acute myeloid leukemia: an experience of Tata Memorial Hospital.
Ghosh S; Shinde SC; Kumaran GS; Sapre RS; Dhond SR; Badrinath Y; Ansari R; Kumar A; Mahadik S; Chougule AB; Nair CN
Indian J Cancer; 2003; 40(2):71-6. PubMed ID: 14716122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
